A Randomised, Parallel Group Treatment, Double-blind, 3-arm Study to Investigate the Comparative PK, Safety, Immunogenicity, and Tolerability Between AVT80 and Entyvio® in Healthy Male and Female Participants Aged 18 to 55 Years Inclusive
Latest Information Update: 10 Oct 2025
At a glance
- Drugs AVT 80 (Primary) ; Vedolizumab
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Alvotech
Most Recent Events
- 24 Sep 2025 Planned End Date changed from 1 Oct 2025 to 1 Jan 2026.
- 24 Sep 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Jan 2026.
- 16 Sep 2025 Status changed from recruiting to active, no longer recruiting.